The 36-month beta value for RLYB is also noteworthy at -1.17. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 3 rating it as “hold”, and 0 rating it as “sell”.
The public float for RLYB is 19.88M, and at present, short sellers hold a 1.66% of that float. The average trading volume of RLYB on July 08, 2025 was 200.92K shares.
RLYB stock’s latest price update
The stock price of Rallybio Corp (NASDAQ: RLYB) has jumped by 32.02% compared to previous close of $0.34. Despite this, the company has seen a gain of 32.96% in its stock price over the last five trading days. benzinga.com reported 2025-07-08 that Rallybio Corporation RLYB agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals Inc. RXRX.
RLYB’s Market Performance
RLYB’s stock has risen by 32.96% in the past week, with a monthly rise of 32.49% and a quarterly drop of -0.13%. The volatility ratio for the week is 5.76% while the volatility levels for the last 30 days are 13.35% for Rallybio Corp The simple moving average for the last 20 days is 29.42% for RLYB’s stock, with a simple moving average of -38.74% for the last 200 days.
Analysts’ Opinion of RLYB
H.C. Wainwright gave a rating of “Buy” to RLYB, setting the target price at $18 in the report published on April 17th of the previous year.
RLYB Trading at 36.03% from the 50-Day Moving Average
After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.82% of loss for the given period.
Volatility was left at 13.35%, however, over the last 30 days, the volatility rate increased by 5.76%, as shares surge +19.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.33% upper at present.
During the last 5 trading sessions, RLYB rose by +40.00%, which changed the moving average for the period of 200-days by -56.98% in comparison to the 20-day moving average, which settled at $0.3484. In addition, Rallybio Corp saw -64.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Rallybio Corp, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for RLYB
Current profitability levels for the company are sitting at:
- -59.41% for the present operating margin
- 0.92% for the gross margin
The net margin for Rallybio Corp stands at -56.82%. The total capital return value is set at -0.93%. Equity return is now at value -67.28%, with -61.25% for asset returns.
Based on Rallybio Corp (RLYB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -379.57.
Currently, EBITDA for the company is -60.5 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 5.98. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.68.
Conclusion
In summary, Rallybio Corp (RLYB) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
